These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18793592)

  • 1. Bioequivalence of Jusline following subcutaneous administration in healthy subjects.
    Al-Rubeaan KA; Al-Daghri NM; Alkharfy KM; Al-Attas OS; Hanif FS; Metias NS; Sabico SL
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):382-8. PubMed ID: 18793592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
    Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
    Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
    Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
    Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
    Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
    Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucodynamics and pharmacokinetics of 70/30 vs. 50/50 NPH/regular insulin mixtures after subcutaneous injection.
    Krug EI; DeRiso L; Tedesco MB; Rao H; Korytkowski MT
    Diabetes Care; 2001 Sep; 24(9):1694-5. PubMed ID: 11522727
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
    Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
    Scholtz HE; Pretorius SG; Wessels DH; Becker RH
    Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
    Andersen G; Singh G; Murugesan SMN; Gogineni R; Sharma N; Panda J; Marwah A; Loganathan S; Athalye SN
    Diabetes Obes Metab; 2023 Jun; 25(6):1485-1494. PubMed ID: 36708333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation.
    Mudaliar SR; Mohideen P; Baxi SC; Joyce M; Armstrong DA; Strange P; Henry RR
    Clin Ther; 2001 Mar; 23(3):404-12. PubMed ID: 11318075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures.
    Davis SN; Thompson CJ; Brown MD; Home PD; Alberti KG
    Diabetes Res Clin Pract; 1991 Aug; 13(1-2):107-17. PubMed ID: 1773708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
    Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
    Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.
    Heise T; Weyer C; Serwas A; Heinrichs S; Osinga J; Roach P; Woodworth J; Gudat U; Heinemann L
    Diabetes Care; 1998 May; 21(5):800-3. PubMed ID: 9589244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures.
    Woodworth JR; Howey DC; Bowsher RR; Brunelle RL; Rowe HM; Compton J; Cerimele B
    Diabetes Care; 1994 May; 17(5):366-71. PubMed ID: 8062601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling.
    Woodworth JR; Howey DC; Bowsher RR
    Diabetes Care; 1994 Jan; 17(1):64-9. PubMed ID: 8112192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.